Ascentage Pharma Group International (AAPG) Receivables (2023 - 2026)

Ascentage Pharma Group International's Receivables history runs 3 years deep, the most recent figure standing at $35.9 million for Q4 2025.

• In Q4 2025, Receivables rose 188.58% year-over-year to $35.9 million; the TTM figure through Dec 2025 stood at $35.9 million (up 188.58% YoY), while the FY2025 annual figure was $35.4 million, up 184.81% from the prior year.
• Receivables for Q4 2025 stood at $35.9 million, up from $10.9 million in the prior quarter.
• The five-year high for Receivables was $35.9 million in Q4 2025, with the low at $10.9 million in Q2 2025.
• The 3-year median for Receivables is $16.8 million (2024), against an average of $20.1 million.
• The sharpest annual moves came in 2024 and 2025: Receivables slumped 41.33% in 2024, then soared 188.58% in 2025.
• Ascentage Pharma Group International's Receivables stood at $21.2 million in 2023, then plunged by 41.33% to $12.4 million in 2024, then surged by 188.58% to $35.9 million in 2025.
• Business Quant data shows AAPG's Receivables at $35.9 million in Q4 2025, $10.9 million in Q2 2025, and $12.4 million in Q4 2024.